Education
About Us
Working with TipRanks
Follow Us
BIOLASE (BIOLQ)
OTHER OTC:BIOLQ
BIOLQ Stock Chart & Stats
$0.01
<$0.01(5.11%)
At close: 4:00 PM EST
$0.01
<$0.01(5.11%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.10
Previous CloseN/A
Volume107.64K
Average Volume (3M)69.31K
Market Cap
$37.00
Enterprise Value$16.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta91.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,597,336
10 Day Avg. Volume87,374
30 Day Avg. Volume69,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap444.41K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product InnovationBIOLASE's focus on innovative dental laser systems positions it well in the medical device sector, offering minimally invasive solutions that can drive long-term adoption and market share growth.
Market PositionBy specializing in dental applications within the medical device sector, BIOLASE can leverage its expertise to maintain a competitive edge and potentially expand its market presence.
Revenue DiversificationBIOLASE's diversified revenue streams, including product sales, training, and partnerships, provide a stable foundation for long-term growth and resilience against market fluctuations.
Bears Say
Financial ChallengesOngoing financial challenges, including persistent losses and high leverage, threaten BIOLASE's financial stability and ability to invest in growth opportunities.
Cash Flow IssuesChronic negative free cash flow indicates inefficiencies in cash management, which could hinder BIOLASE's ability to sustain operations and invest in future growth.
Revenue DeclineThe decline in revenue growth reflects challenges in market expansion and customer acquisition, potentially impacting BIOLASE's long-term competitiveness and profitability.
BIOLASE News
BIOLQ FAQ
What was BIOLASE’s price range in the past 12 months?
BIOLASE lowest stock price was <$0.01 and its highest was $0.10 in the past 12 months.
What is BIOLASE’s market cap?
BIOLASE’s market cap is $37.00.
When is BIOLASE’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BIOLASE’s earnings last quarter?
Currently, no data Available
Is BIOLASE overvalued?
According to Wall Street analysts BIOLASE’s price is currently Overvalued.
Does BIOLASE pay dividends?
BIOLASE does not currently pay dividends.
What is BIOLASE’s EPS estimate?
BIOLASE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BIOLASE have?
BIOLASE has 36,597,336 shares outstanding.
What happened to BIOLASE’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BIOLASE?
Currently, no hedge funds are holding shares in BIOLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BIOLASE
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
Technical Analysis
Venus Concept
―
Enveric Biosciences
―
IN8bio
―
Dermata Therapeutics
―
Bluejay Diagnostics
―
Ownership Overview
―
Insiders
0.44% Other Institutional Investors
99.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---